Point of View Deficient Neuroendocrine Regulation of the Cardiovascular System With Advancing Age in Healthy Humans
Edward G. Lakatta, MD T he convergence of several lines of evidence clearly indicates that advancing age in healthy humans and animals is accompanied by a deterioration of the communication between the nervous system and the heart and vasculature.1 Specifically, the efficacy of 13-adrenergic modulation of cardiovascular function decreases with aging. As circulatory catecholamine levels do not decline or are increased with aging,2-9 particularly during stress, the age-associated deficit in the effectiveness of /3-adrenergic control is largely postsynaptic in nature. Thus, infusions of f8-adrenergic agonists elicit a lesser increase in heart rate, lesser increases in left ventricular ejection fraction (LVEF) and cardiac output, and reduced vasodilatory responses in older versus younger sedentary men.1 5 The magnitude of the age-associated deficits in these responses ranges from 30% to 50% (Figure 110-12 ). However, reflex responses complicate the interpretation of infusion studies.1314 In this regard, it is noteworthy that age-associated changes in parasympathetic control of the heart and circulation have been inferred from several studies. Still, in a beagle model it has been shown that a reduction in the maximum isoproterenolinduced heart rate increase in older versus younger dogs does persist in the presence of vagal blockade. 15 In probing for age-associated differences in cardiovascular regulatory mechanisms, it is often extremely difficult to separate out the effects of disease and lifestyle (e.g., fitness) from those of aging. Recent studies have used healthy older volunteers highly screened before study to exclude occult coronary artery disease, a common finding in older individuals.5 '16-19 It is unlikely that impairment of j-adrenergic modulation of cardiovascular function with aging is a result of the well-known decrease in physical fitness associated with a sedentary lifestyle that generally accompanies aging, because ageassociated deficits in response to isoproterenol infusions persist after intensive exercise training.5
In addition to a diminished response to 1B-adrenergic agonist infusions at rest, an age-associated impairment of 3-adrenergic regulation of the heart and circulation also becomes apparent during stress, e.g., with assumption of the upright posture or during exercise, when the P-adrenergic component of neural cardiovascular control predominates and the parasympathetic component wanes.
The precise role of 3-adrenergic modulation during dynamic exercise in the upright posture has been ascertained by exercising individuals in the presence of ,3-adrenergic blockade. When younger individuals exercise in the presence of propranolol, their heart rate increases to a lesser extent but their end-diastolic volume (EDV) increases substantially, and a greater stroke volume is achieved than in the absence of p8-blockade.20 Additionally, the left ventricular (LV) end-systolic volume (ESV) reduction that normally accompanies exercise is blunted. The hemodynamic profile during upright cycle exercise in healthy older men has been observed to differ from that in younger men in a way that resembles the profile observed during 8-adrenergic blockade ( Figure 2 ). Specifically, during exercise in healthy, sedentary older individuals the heart rate increase is blunted, the EDV and ESV are enhanced, and the LVEF is blunted relative to younger individuals.16'17 Thus, the blunted cardiac responses in older men to an infusion of a /3-adrenergic agonist at rest has "naturally occurring" counterparts during acute exercise stress. Moreover, when older and younger men exercise in the presence of propranolol, the age-associated decline in heart rate is markedly reduced (because of a greater drug-induced reduction in younger than in older men after propranolol), and the age-associated ventricular dilatation is abolished (because of a greater ventricular dilatation in younger men than in older men after administration of propranolol).18 The age-associated decrease in the peak LV filling rate is also abolished during exercise in the presence of propranolol. 19 Additional studies have shown that the cardiac output differences between older and younger subjects during exercise also become attenuated in the presence of /3-adrenergic blockade.21
The failure of the LVEF of older subjects to increase to the same extent as in younger ones after the infusion of a 13-adrenergic agonists or during exercise is due to a failure of the ESV to decrease in the former to the extent that it did in the latter.22 This could result from an age-associated decrease in the p-adrenergic stimulation-mediated increase in LV contractility or from age-associated increases in the vascular or cardiac components of LV afterload. The cardiac component of ISOPRENALINE INTRA-ARTERIALLY ISOPROTERENOL (ng/min) (ng min1 100 mi-1) FIGURE 1. Panel A: Effect of bolus intravenous isoproterenol infusions to increase heart rate in healthy young and older men at rest (from Yin et all0). Panel B.: Effect of isoproterenol to increase left ventricular ejection fraction (LVEF) in younger and older healthy men in the supine position before (pre) and after (post) chronic endurance training. Endurance training had no effect on this index of cardiac pump function or on its response to isoproterenol (from Stratton et al5). Panel C: Effect of intra-arterial isoproterenol (isoprenaline) infusions to decrease the forearm vascular resistance in healthy younger and older men (from van Brummelen et all'). Panel D: Effect of intravenous arterial infusion of isoproterenol to relax dorsal hand veins previously constricted by phenylephrine in men of varying age (from Pan et al12).
afterload, which is related to heart size, may increase with age as EDV has been found to increase with age in men both at rest and during exercise, particularly in the upright position16'17 ( Figure 2 ). Vascular components of cardiac afterload also increase with aging. This is due to increases in vascular stiffening, reflected pulse waves, and in some23,24 but not all16 older individuals, to an increase in peripheral vascular resistance. Whether infusion of /8-adrenergic agonists or exhaustive exercise alters vascular impedance to different extents in younger versus older men cannot be ascertained from measurements of brachial systolic pressure because the relation of the peripheral to central aortic pressure shifts with aging because of a large increase to early reflected pulse waves in older individuals.23 It is noteworthy, however, that an age-associated increase in aortic impedance during treadmill exercise occurs in beagles and is abolished during exercise in the presence of propranolol. 25 The extent to which the myocardial contractility index, systolic blood pressure (SBP)/ESV, increases during exercise decreases with aging.1618 The magnitude of this age deficit is reduced during exercise in the presence of f8-adrenergic blockade.18 In excised myocardial tissue or in isolated heart cells, it has been well established that P-adrenergic receptor (p-AR) stimulation produces less of an increase in contraction ampli-tude and velocity in preparations isolated from older versus younger donors26-29 ( Figure 330 ). a1-Adrenergic agonists and other peptides, e.g., adenosine, opioid peptides, and cholinergic agonists, can modulate the effects of P-AR stimulation on heart contraction. The precise role of postsynaptic interactions among a-and 3-adrenergic and cholinergic agonists and the other peptide receptor agonists to modulate the age-associated decline in the cardiac response to /3-AR stimulation is presently not well understood. However, it has recently been demonstrated that the negative contractile and chronotropic responses to exogenous adenosine are increased with age in guinea pigs.31 Adenosine release from aged rat hearts (12-22 months) is also greater than that of younger rat hearts (3-5 months). 32 Since adenosine has an antiadrenergic action, i.e., it reduces the 3-adrenoceptor-induced increase in cAMP and subsequent increase in cAMPdependent protein kinase (PK), Ca21 current, and contractility,33-37 enhanced adenosine levels in the aged myocardium may be responsible, in part, for the diminished contractile responsiveness of the older adult heart to /8-AR stimulation.32 However, it is unlikely that age-associated changes in adenosine metabolism can directly account for age-associated differences in the ,8-AR stimulation of isolated cardiac muscle or cardiocytes (Figure 3 ). The richly documented age-associated reduction in the postsynaptic response of the cardiovascular system to /-AR stimulation in human and animal tissues and cells appears to be due to multiple changes in molecular and biochemical receptor coupling and postreceptor mechanisms rather than to a major modification of a single rate-limiting step, as might occur, for example, in a genetic defect. One change within the /3-AR system is a decrease in the receptor affinity for agonists938-44 without substantial changes in /-AR density being observed in MoSt2638394546 but not all47 studies. However, there is little information available regarding changes of /-AR subtype density, affinity, or functional regulation in aging. The postreceptor changes with aging include decreases in the activities of G,-protein and adenylate cyclase catalytic unit and a decrease in the cAMP-dependent PK activity (PKA)-induced protein phosphorylation.3839,41,43,48-53 Recent studies indicate that the relative failure of /-AR stimulation to augment contractility of cardiac cells from old versus young rat hearts is due to a reduction in the /-ARstimulated increase in Ca21 influx via the L-type sarcolemmal Ca21 channels and to a reduction in the increase in the amplitude of the cytosolic Ca21 transient amplitude after /-AR stimulation of ventricular myocytes from older versus younger hearts. 27 It has long been recognized that prolonged exposure of myocardial tissue to ,8-AR agonists modifies the ,3-AR responsiveness. A rapid heterologous desensitization of /3-AR receptors occurs upon their phosphorylation by cAMP-dependent PK. In contrast, a rapid homologous pattern of the desensitization is mediated primarily by phosphorylation of the p-AR by a newly described cAMP-independent enzyme, /3-adrenergic kinase (/3-ARK).54-57 At high agonist (micromolar) concentrations, /-ARK is activated and phosphorylates /3-AR.54-58 Recently, it was found that an arrestin-like protein, barrestin, is present in all examined tissues with a distribution similar to that of /3-ARK. Barrestin can bind to and inactivate the /-ARK-phosphorylated /3-AR, thus causing homologous desensitization.59 A change in the GQ/G ratio may also be involved in heterologous desensitization.56,60-64 Thus, desensitization of /8-AR stimulation occurs via modifications of both receptor and postreceptor events.
A comparison of such /3-AR desensitization and the reduced efficacy of /-AR stimulation with aging ( Figure  4 ) suggests that the age-associated alterations may, at least in part, be caused by a desensitization of the /-AR adenylate cyclase system. As noted above, in both humans and animals, plasma catecholamine levels, especially plasma norepinephrine, are increased in older versus younger organisms during perturbations from the basal state.2-9 Chronic elevations of plasma catecholamines in older individuals caused by excessive neural discharge and reduced clearance might induce /3-AR desensitization. Although most studies have shown that the /3-AR density does not change with aging, the affinity of the receptor for agonists decreases, and coupling of receptor to the catalytic subunit also decreases, as noted above. The acute elevation of endogenous plasma catecholamines in humans associated with assumption of the upright posture decreases the proportion of high-affinity /3-AR in lymphocytes in younger but not in older individuals.9 A desensitization of /3-AR mechanisms in older individuals in the supine position before the postural change could, in part, explain this result. In this regard, it has been noted that catecholamine desensitization of the rat myocardium induced by the chronic in vivo administration of a ,8-adrenergic agonist occurs to a lesser extent in hearts of senescent than in hearts of younger rats; this has been also interpreted to indicate that the /3-AR system of aged rat myocardium had been partially desensitized before the study.41 Whether and how /3-ARK, barrestin, and Gi-protein activities change with age is presently unknown.
In severe chronic heart failure of various causes, an increase in the activity of the sympathetic nervous system in response to the reduced cardiac output is a general adaptive mechanism to maintain pressure and flow requirements of the organism. Studies in patients suffering from heart failure and in experimental models of chronic heart failure6566 have demonstrated that plasma norepinephrine levels are elevated and that myocardial catecholamines become depleted. Although this increased sympathetic activity may be initially helpful for the chronically failing heart, it can simultaneously lead to a desensitization of /-AR. In experimental models of heart failure induced by pressure overloading or pacing overdrive, it has been reported recently that [NE] FIGURE 3. PanelA: Effect ofnorepinephrine on the maximum rate ofisometric tension development in isolated trabeculae from hearts of varying ages (from Lakatta et a128). Panel B: Effect of norepinephrine on twitch amplitude during the electrically stimulated twitch in single cardiac myocytes isolated from hearts of rats of varying ages (from Sakai et a129). Panel C: Effect of norepinephrine (NE) to increase the phosphorylation of troponin I (TNI) in suspensions ofheart cells isolated from hearts ofrats ofvarying ages as in above panels (from Sakai et a130). Panels B and C: Norepinephrine stimulated 1-receptors; prazosin had no effect on the results. the total 3-AR number is decreased. [67] [68] [69] In heart failure in humans, the number of cardiac 13-adrenoceptors is also decreased, especially that of 81-adrenoceptors,70,71 and it has been speculated that this selective A31-adrenoceptor decrease might be caused by high levels of plasma norepinephrine, which is a rather selective f31-adrenoceptor agonist. In addition, it has also been noted that in failing human hearts, there is a selective decline in the high-affinity f3-ARs as well as a decrease in the coupling of receptors with the GQprotein. 72 When these changes in the 3-AR system in heart failure patients are compared with the characteristics of age-associated alterations in 3-modulation of cardiac function, the similarities become very evident (Figure 4 ). In healthy, aged humans and in those with chronic heart failure, reduction in the effectiveness of f-adrenergic modulation of heart rate and myocardial contractility occur. It has been suggested recently that age is the dominant variable in the reduced P3-adrenergic augmentation in cardiac cells isolated from the failing human heart. 73 The kinetics of myocardial Ca21 cycling are also altered in human cardiomyopathy,74 and many strikingly similar changes in excitation-contraction mechanisms occur in the healthy, aged heart and in the chronically failing heart. 74 The magnitude of the j3-adrenergic deficit in healthy older humans is often as severe as that measured in chronic heart failure. Should we then refer to the heart of older individuals as a "neurocardiomyopathy of aging"? I think not, because the adrenergic impairment in healthy adults, per se, does not lead to nor is it accompanied by a marked reduction in the overall cardiovascular reserve capacity. Rather, healthy older individuals are capable of sustained vigorous exercise albeit possibly at a higher LV filling pressure. This underscores the notion that the cardiac ,8-AR "desensitization" that accompanies chronic heart failure cannot be a cause of heart failure but rather may modulate the cardiac response to specific pathophysiological states. In this regard, the severely blunted 13-AR response in healthy older individuals will undoubtedly affect the cardiovascular response to the stress of various disease states and impact the clinical manifestations of early stages of disease and its progression.
